Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 11—November 2010

Lymphotropism of Merkel Cell Polyomavirus Infection, Nova Scotia, Canada

Sonia Toracchio, Annette Foyle, Vojtech Sroller1, Jon A. Reed, Jun Wu, Claudia A. Kozinetz, and Janet S. ButelComments to Author 
Author affiliations: Baylor College of Medicine, Houston, Texas, USA (S. Toracchio, V. Sroller, J.A. Reed, C.A. Kozinez, J.S. Butel); Dalhousie University, Halifax, Nova Scotia, Canada (A. Foyle); Queen Elizabeth II Health Science Center, Halifax (A. Foyle); and Public Health Agency of Canada, Ottawa, Ontario, Canada (J. Wu); 1Current affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic

Main Article

Table 5

Clinical outcomes for lymphoma patients over a 5-year period, Nova Scotia, Canada*

Characteristics No. (%) MCPyV positive No. (%) MCPyV negative p value
Disease stage†
I 2 (28.6) 35 (35.4)
II 2 (28.6) 14 (14.1)
III 0 11 (11.1)
3 (42.9)
39 (39.4)
Patient survival
Alive in remission 3 (42.9) 38 (35.5)
Alive with disease 1 (14.3) 23 (21.5)
Died from disease 3 (42.9) 46 (43.0) 0.88

*The 5-year period refers to the time frame for each patient from time of diagnosis until follow-up 5 years later. MCPyV, Merkel cell polyomavirus.
†Clinical stage of disease at time of lymphoma diagnosis; information was not available for 8 MCPyV-negative patients.

Main Article

Page created: March 08, 2011
Page updated: March 08, 2011
Page reviewed: March 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.